Table of Content

1 Transdermal Therapeutic Systems (TTS) Market Overview
1.1 Product Overview and Scope of Transdermal Therapeutic Systems (TTS)
1.2 Transdermal Therapeutic Systems (TTS) Segment by Type
1.2.1 Global Transdermal Therapeutic Systems (TTS) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Methyl Salicylate
1.2.3 Nitroglycerin
1.2.4 Fentanyl
1.2.5 Nicotine
1.2.6 Rivastigmine
1.2.7 Estradiol
1.2.8 Others
1.3 Transdermal Therapeutic Systems (TTS) Segment by Application
1.3.1 Transdermal Therapeutic Systems (TTS) Sales Comparison by Application: (2021-2027)
1.3.2 OTC Channel
1.3.3 Retail Channel
1.3.4 E-Commerce Channel
1.4 Global Transdermal Therapeutic Systems (TTS) Market Size Estimates and Forecasts
1.4.1 Global Transdermal Therapeutic Systems (TTS) Revenue 2016-2027
1.4.2 Global Transdermal Therapeutic Systems (TTS) Sales 2016-2027
1.4.3 Transdermal Therapeutic Systems (TTS) Market Size by Region: 2016 Versus 2021 Versus 2027

2 Transdermal Therapeutic Systems (TTS) Market Competition by Manufacturers
2.1 Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Manufacturers (2016-2021)
2.2 Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Transdermal Therapeutic Systems (TTS) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Transdermal Therapeutic Systems (TTS) Manufacturing Sites, Area Served, Product Type
2.5 Transdermal Therapeutic Systems (TTS) Market Competitive Situation and Trends
2.5.1 Transdermal Therapeutic Systems (TTS) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Transdermal Therapeutic Systems (TTS) Players Market Share by Revenue
2.5.3 Global Transdermal Therapeutic Systems (TTS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Transdermal Therapeutic Systems (TTS) Retrospective Market Scenario by Region
3.1 Global Transdermal Therapeutic Systems (TTS) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Transdermal Therapeutic Systems (TTS) Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Transdermal Therapeutic Systems (TTS) Market Facts & Figures by Country
3.3.1 North America Transdermal Therapeutic Systems (TTS) Sales by Country
3.3.2 North America Transdermal Therapeutic Systems (TTS) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Transdermal Therapeutic Systems (TTS) Market Facts & Figures by Country
3.4.1 Europe Transdermal Therapeutic Systems (TTS) Sales by Country
3.4.2 Europe Transdermal Therapeutic Systems (TTS) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Transdermal Therapeutic Systems (TTS) Market Facts & Figures by Region
3.5.1 Asia Pacific Transdermal Therapeutic Systems (TTS) Sales by Region
3.5.2 Asia Pacific Transdermal Therapeutic Systems (TTS) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Transdermal Therapeutic Systems (TTS) Market Facts & Figures by Country
3.6.1 Latin America Transdermal Therapeutic Systems (TTS) Sales by Country
3.6.2 Latin America Transdermal Therapeutic Systems (TTS) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Transdermal Therapeutic Systems (TTS) Market Facts & Figures by Country
3.7.1 Middle East and Africa Transdermal Therapeutic Systems (TTS) Sales by Country
3.7.2 Middle East and Africa Transdermal Therapeutic Systems (TTS) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Transdermal Therapeutic Systems (TTS) Historic Market Analysis by Type
4.1 Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Type (2016-2021)
4.2 Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Type (2016-2021)
4.3 Global Transdermal Therapeutic Systems (TTS) Price by Type (2016-2021)

5 Global Transdermal Therapeutic Systems (TTS) Historic Market Analysis by Application
5.1 Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Application (2016-2021)
5.2 Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Application (2016-2021)
5.3 Global Transdermal Therapeutic Systems (TTS) Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Hisamitsu
6.1.1 Hisamitsu Corporation Information
6.1.2 Hisamitsu Description and Business Overview
6.1.3 Hisamitsu Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Hisamitsu Product Portfolio
6.1.5 Hisamitsu Recent Developments/Updates
6.2 Mylan
6.2.1 Mylan Corporation Information
6.2.2 Mylan Description and Business Overview
6.2.3 Mylan Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Mylan Product Portfolio
6.2.5 Mylan Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 GSK Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novartis Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Teve (Actavis)
6.5.1 Teve (Actavis) Corporation Information
6.5.2 Teve (Actavis) Description and Business Overview
6.5.3 Teve (Actavis) Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Teve (Actavis) Product Portfolio
6.5.5 Teve (Actavis) Recent Developments/Updates
6.6 Nitto Denko
6.6.1 Nitto Denko Corporation Information
6.6.2 Nitto Denko Description and Business Overview
6.6.3 Nitto Denko Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Nitto Denko Product Portfolio
6.6.5 Nitto Denko Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Johnson & Johnson Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Lohmann
6.8.1 Lohmann Corporation Information
6.8.2 Lohmann Description and Business Overview
6.8.3 Lohmann Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Lohmann Product Portfolio
6.8.5 Lohmann Recent Developments/Updates
6.9 Teikoku Seiyaku
6.9.1 Teikoku Seiyaku Corporation Information
6.9.2 Teikoku Seiyaku Description and Business Overview
6.9.3 Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Teikoku Seiyaku Product Portfolio
6.9.5 Teikoku Seiyaku Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Corporation Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Pfizer Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Bayer
6.11.1 Bayer Corporation Information
6.11.2 Bayer Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.11.3 Bayer Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Bayer Product Portfolio
6.11.5 Bayer Recent Developments/Updates
6.12 Lingrui
6.12.1 Lingrui Corporation Information
6.12.2 Lingrui Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.12.3 Lingrui Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Lingrui Product Portfolio
6.12.5 Lingrui Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Corporation Information
6.13.2 Sanofi Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.13.3 Sanofi Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Sanofi Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 UCB Pharma
6.14.1 UCB Pharma Corporation Information
6.14.2 UCB Pharma Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.14.3 UCB Pharma Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.14.4 UCB Pharma Product Portfolio
6.14.5 UCB Pharma Recent Developments/Updates
6.15 Dr. Reddy's Laboratories
6.15.1 Dr. Reddy's Laboratories Corporation Information
6.15.2 Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.15.3 Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Dr. Reddy's Laboratories Product Portfolio
6.15.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.16 Qizheng
6.16.1 Qizheng Corporation Information
6.16.2 Qizheng Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.16.3 Qizheng Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Qizheng Product Portfolio
6.16.5 Qizheng Recent Developments/Updates
6.17 Endo
6.17.1 Endo Corporation Information
6.17.2 Endo Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.17.3 Endo Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Endo Product Portfolio
6.17.5 Endo Recent Developments/Updates
6.18 Mundipharma
6.18.1 Mundipharma Corporation Information
6.18.2 Mundipharma Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.18.3 Mundipharma Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Mundipharma Product Portfolio
6.18.5 Mundipharma Recent Developments/Updates
6.19 Huarun 999
6.19.1 Huarun 999 Corporation Information
6.19.2 Huarun 999 Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.19.3 Huarun 999 Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Huarun 999 Product Portfolio
6.19.5 Huarun 999 Recent Developments/Updates
6.20 Haw Par
6.20.1 Haw Par Corporation Information
6.20.2 Haw Par Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.20.3 Haw Par Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Haw Par Product Portfolio
6.20.5 Haw Par Recent Developments/Updates
6.21 Nichiban
6.21.1 Nichiban Corporation Information
6.21.2 Nichiban Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.21.3 Nichiban Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Nichiban Product Portfolio
6.21.5 Nichiban Recent Developments/Updates
6.22 Mentholatum Company
6.22.1 Mentholatum Company Corporation Information
6.22.2 Mentholatum Company Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.22.3 Mentholatum Company Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.22.4 Mentholatum Company Product Portfolio
6.22.5 Mentholatum Company Recent Developments/Updates
6.23 Laboratoires Genevrier
6.23.1 Laboratoires Genevrier Corporation Information
6.23.2 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.23.3 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.23.4 Laboratoires Genevrier Product Portfolio
6.23.5 Laboratoires Genevrier Recent Developments/Updates
6.24 Beijing Tide Pharmaceutical
6.24.1 Beijing Tide Pharmaceutical Corporation Information
6.24.2 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.24.3 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.24.4 Beijing Tide Pharmaceutical Product Portfolio
6.24.5 Beijing Tide Pharmaceutical Recent Developments/Updates
6.25 Luye Pharma Group
6.25.1 Luye Pharma Group Corporation Information
6.25.2 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Description and Business Overview
6.25.3 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2016-2021)
6.25.4 Luye Pharma Group Product Portfolio
6.25.5 Luye Pharma Group Recent Developments/Updates

7 Transdermal Therapeutic Systems (TTS) Manufacturing Cost Analysis
7.1 Transdermal Therapeutic Systems (TTS) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Transdermal Therapeutic Systems (TTS)
7.4 Transdermal Therapeutic Systems (TTS) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Transdermal Therapeutic Systems (TTS) Distributors List
8.3 Transdermal Therapeutic Systems (TTS) Customers

9 Transdermal Therapeutic Systems (TTS) Market Dynamics
9.1 Transdermal Therapeutic Systems (TTS) Industry Trends
9.2 Transdermal Therapeutic Systems (TTS) Growth Drivers
9.3 Transdermal Therapeutic Systems (TTS) Market Challenges
9.4 Transdermal Therapeutic Systems (TTS) Market Restraints

10 Global Market Forecast
10.1 Transdermal Therapeutic Systems (TTS) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Transdermal Therapeutic Systems (TTS) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Transdermal Therapeutic Systems (TTS) by Type (2022-2027)
10.2 Transdermal Therapeutic Systems (TTS) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Transdermal Therapeutic Systems (TTS) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Transdermal Therapeutic Systems (TTS) by Application (2022-2027)
10.3 Transdermal Therapeutic Systems (TTS) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Transdermal Therapeutic Systems (TTS) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Transdermal Therapeutic Systems (TTS) by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Transdermal Therapeutic Systems (TTS) Sales (M Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Transdermal Therapeutic Systems (TTS) Sales (M Units) Comparison by Application (2021-2027)
Table 3. Global Transdermal Therapeutic Systems (TTS) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Transdermal Therapeutic Systems (TTS) Covered in This Study
Table 5. Global Transdermal Therapeutic Systems (TTS) Sales (M Units) of Key Manufacturers (2016-2021)
Table 6. Global Transdermal Therapeutic Systems (TTS) Sales Share by Manufacturers (2016-2021)
Table 7. Global Transdermal Therapeutic Systems (TTS) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Transdermal Therapeutic Systems (TTS) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Transdermal Therapeutic Systems (TTS) Average Price (USD/K Units) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Transdermal Therapeutic Systems (TTS) Manufacturing Sites and Area Served
Table 11. Manufacturers Transdermal Therapeutic Systems (TTS) Product Type
Table 12. Global Transdermal Therapeutic Systems (TTS) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Transdermal Therapeutic Systems (TTS) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transdermal Therapeutic Systems (TTS) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Transdermal Therapeutic Systems (TTS) Sales by Region (2016-2021) & (M Units)
Table 16. Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Region (2016-2021)
Table 17. Global Transdermal Therapeutic Systems (TTS) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Transdermal Therapeutic Systems (TTS) Sales by Country (2016-2021) & (M Units)
Table 19. North America Transdermal Therapeutic Systems (TTS) Sales Market Share by Country (2016-2021)
Table 20. North America Transdermal Therapeutic Systems (TTS) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Transdermal Therapeutic Systems (TTS) Revenue Market Share by Country (2016-2021)
Table 22. Europe Transdermal Therapeutic Systems (TTS) Sales by Country (2016-2021) & (M Units)
Table 23. Europe Transdermal Therapeutic Systems (TTS) Sales Market Share by Country (2016-2021)
Table 24. Europe Transdermal Therapeutic Systems (TTS) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Transdermal Therapeutic Systems (TTS) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Transdermal Therapeutic Systems (TTS) Sales by Region (2016-2021) & (M Units)
Table 27. Asia Pacific Transdermal Therapeutic Systems (TTS) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Transdermal Therapeutic Systems (TTS) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Transdermal Therapeutic Systems (TTS) Revenue Market Share by Region (2016-2021)
Table 30. Latin America Transdermal Therapeutic Systems (TTS) Sales by Country (2016-2021) & (M Units)
Table 31. Latin America Transdermal Therapeutic Systems (TTS) Sales Market Share by Country (2016-2021)
Table 32. Latin America Transdermal Therapeutic Systems (TTS) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Transdermal Therapeutic Systems (TTS) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Transdermal Therapeutic Systems (TTS) Sales by Country (2016-2021) & (M Units)
Table 35. Middle East and Africa Transdermal Therapeutic Systems (TTS) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Transdermal Therapeutic Systems (TTS) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Transdermal Therapeutic Systems (TTS) Revenue Market Share by Country (2016-2021)
Table 38. Global Transdermal Therapeutic Systems (TTS) Sales (M Units) by Type (2016-2021)
Table 39. Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Type (2016-2021)
Table 40. Global Transdermal Therapeutic Systems (TTS) Revenue (Million US$) by Type (2016-2021)
Table 41. Global Transdermal Therapeutic Systems (TTS) Revenue Share by Type (2016-2021)
Table 42. Global Transdermal Therapeutic Systems (TTS) Price (USD/K Units) by Type (2016-2021)
Table 43. Global Transdermal Therapeutic Systems (TTS) Sales (M Units) by Application (2016-2021)
Table 44. Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Application (2016-2021)
Table 45. Global Transdermal Therapeutic Systems (TTS) Revenue (Million US$) by Application (2016-2021)
Table 46. Global Transdermal Therapeutic Systems (TTS) Revenue Share by Application (2016-2021)
Table 47. Global Transdermal Therapeutic Systems (TTS) Price (USD/K Units) by Application (2016-2021)
Table 48. Hisamitsu Corporation Information
Table 49. Hisamitsu Description and Business Overview
Table 50. Hisamitsu Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 51. Hisamitsu Transdermal Therapeutic Systems (TTS) Product
Table 52. Hisamitsu Recent Developments/Updates
Table 53. Mylan Corporation Information
Table 54. Mylan Description and Business Overview
Table 55. Mylan Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 56. Mylan Transdermal Therapeutic Systems (TTS) Product
Table 57. Mylan Recent Developments/Updates
Table 58. GSK Corporation Information
Table 59. GSK Description and Business Overview
Table 60. GSK Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 61. GSK Transdermal Therapeutic Systems (TTS) Product
Table 62. GSK Recent Developments/Updates
Table 63. Novartis Corporation Information
Table 64. Novartis Description and Business Overview
Table 65. Novartis Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 66. Novartis Transdermal Therapeutic Systems (TTS) Product
Table 67. Novartis Recent Developments/Updates
Table 68. Teve (Actavis) Corporation Information
Table 69. Teve (Actavis) Description and Business Overview
Table 70. Teve (Actavis) Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 71. Teve (Actavis) Transdermal Therapeutic Systems (TTS) Product
Table 72. Teve (Actavis) Recent Developments/Updates
Table 73. Nitto Denko Corporation Information
Table 74. Nitto Denko Description and Business Overview
Table 75. Nitto Denko Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 76. Nitto Denko Transdermal Therapeutic Systems (TTS) Product
Table 77. Nitto Denko Recent Developments/Updates
Table 78. Johnson & Johnson Corporation Information
Table 79. Johnson & Johnson Description and Business Overview
Table 80. Johnson & Johnson Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 81. Johnson & Johnson Transdermal Therapeutic Systems (TTS) Product
Table 82. Johnson & Johnson Recent Developments/Updates
Table 83. Lohmann Corporation Information
Table 84. Lohmann Description and Business Overview
Table 85. Lohmann Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 86. Lohmann Transdermal Therapeutic Systems (TTS) Product
Table 87. Lohmann Recent Developments/Updates
Table 88. Teikoku Seiyaku Corporation Information
Table 89. Teikoku Seiyaku Description and Business Overview
Table 90. Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 91. Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Product
Table 92. Teikoku Seiyaku Recent Developments/Updates
Table 93. Pfizer Corporation Information
Table 94. Pfizer Description and Business Overview
Table 95. Pfizer Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 96. Pfizer Transdermal Therapeutic Systems (TTS) Product
Table 97. Pfizer Recent Developments/Updates
Table 98. Bayer Corporation Information
Table 99. Bayer Description and Business Overview
Table 100. Bayer Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 101. Bayer Transdermal Therapeutic Systems (TTS) Product
Table 102. Bayer Recent Developments/Updates
Table 103. Lingrui Corporation Information
Table 104. Lingrui Description and Business Overview
Table 105. Lingrui Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 106. Lingrui Transdermal Therapeutic Systems (TTS) Product
Table 107. Lingrui Recent Developments/Updates
Table 108. Sanofi Corporation Information
Table 109. Sanofi Description and Business Overview
Table 110. Sanofi Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 111. Sanofi Transdermal Therapeutic Systems (TTS) Product
Table 112. Sanofi Recent Developments/Updates
Table 113. UCB Pharma Corporation Information
Table 114. UCB Pharma Description and Business Overview
Table 115. UCB Pharma Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 116. UCB Pharma Transdermal Therapeutic Systems (TTS) Product
Table 117. UCB Pharma Recent Developments/Updates
Table 118. Dr. Reddy's Laboratories Corporation Information
Table 119. Dr. Reddy's Laboratories Description and Business Overview
Table 120. Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 121. Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Product
Table 122. Dr. Reddy's Laboratories Recent Developments/Updates
Table 123. Qizheng Corporation Information
Table 124. Qizheng Description and Business Overview
Table 125. Qizheng Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 126. Qizheng Transdermal Therapeutic Systems (TTS) Product
Table 127. Qizheng Recent Developments/Updates
Table 128. Endo Corporation Information
Table 129. Endo Description and Business Overview
Table 130. Endo Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 131. Endo Transdermal Therapeutic Systems (TTS) Product
Table 132. Endo Recent Developments/Updates
Table 133. Mundipharma Corporation Information
Table 134. Mundipharma Description and Business Overview
Table 135. Mundipharma Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 136. Mundipharma Transdermal Therapeutic Systems (TTS) Product
Table 137. Mundipharma Recent Developments/Updates
Table 138. Huarun 999 Corporation Information
Table 139. Huarun 999 Description and Business Overview
Table 140. Huarun 999 Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 141. Huarun 999 Transdermal Therapeutic Systems (TTS) Product
Table 142. Huarun 999 Recent Developments/Updates
Table 143. Haw Par Corporation Information
Table 144. Haw Par Description and Business Overview
Table 145. Haw Par Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 146. Haw Par Transdermal Therapeutic Systems (TTS) Product
Table 147. Haw Par Recent Developments/Updates
Table 148. Nichiban Corporation Information
Table 149. Nichiban Description and Business Overview
Table 150. Nichiban Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 151. Nichiban Transdermal Therapeutic Systems (TTS) Product
Table 152. Nichiban Recent Developments/Updates
Table 153. Mentholatum Company Corporation Information
Table 154. Mentholatum Company Description and Business Overview
Table 155. Mentholatum Company Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 156. Mentholatum Company Transdermal Therapeutic Systems (TTS) Product
Table 157. Mentholatum Company Recent Developments/Updates
Table 158. Laboratoires Genevrier Corporation Information
Table 159. Laboratoires Genevrier Description and Business Overview
Table 160. Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 161. Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Product
Table 162. Laboratoires Genevrier Recent Developments/Updates
Table 163. Beijing Tide Pharmaceutical Corporation Information
Table 164. Beijing Tide Pharmaceutical Description and Business Overview
Table 165. Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 166. Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Product
Table 167. Beijing Tide Pharmaceutical Recent Developments/Updates
Table 168. Luye Pharma Group Corporation Information
Table 169. Luye Pharma Group Description and Business Overview
Table 170. Luye Pharma Group Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 171. Luye Pharma Group Transdermal Therapeutic Systems (TTS) Product
Table 172. Luye Pharma Group Recent Developments/Updates
Table 173. Production Base and Market Concentration Rate of Raw Material
Table 174. Key Suppliers of Raw Materials
Table 175. Transdermal Therapeutic Systems (TTS) Distributors List
Table 176. Transdermal Therapeutic Systems (TTS) Customers List
Table 177. Transdermal Therapeutic Systems (TTS) Market Trends
Table 178. Transdermal Therapeutic Systems (TTS) Growth Drivers
Table 179. Transdermal Therapeutic Systems (TTS) Market Restraints
Table 180. Global Transdermal Therapeutic Systems (TTS) Sales Forecast by Type (2022-2027) & (M Units)
Table 181. Global Transdermal Therapeutic Systems (TTS) Sales Market Share Forecast by Type (2022-2027)
Table 182. Global Transdermal Therapeutic Systems (TTS) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 183. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share Forecast by Type (2022-2027)
Table 184. Global Transdermal Therapeutic Systems (TTS) Sales Forecast by Application (2022-2027) & (M Units)
Table 185. Global Transdermal Therapeutic Systems (TTS) Sales Market Share Forecast by Application (2022-2027)
Table 186. Global Transdermal Therapeutic Systems (TTS) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 187. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share Forecast by Application (2022-2027)
Table 188. Global Transdermal Therapeutic Systems (TTS) Sales Forecast by Region (2022-2027) & (M Units)
Table 189. Global Transdermal Therapeutic Systems (TTS) Sales Market Share Forecast by Region (2022-2027)
Table 190. Global Transdermal Therapeutic Systems (TTS) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 191. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share Forecast by Region (2022-2027)
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Transdermal Therapeutic Systems (TTS)
Figure 2. Global Transdermal Therapeutic Systems (TTS) Market Share by Type in 2020 & 2027
Figure 3. Methyl Salicylate Product Picture
Figure 4. Nitroglycerin Product Picture
Figure 5. Fentanyl Product Picture
Figure 6. Nicotine Product Picture
Figure 7. Rivastigmine Product Picture
Figure 8. Estradiol Product Picture
Figure 9. Others Product Picture
Figure 10. Global Transdermal Therapeutic Systems (TTS) Market Share by Application in 2020 & 2027
Figure 11. OTC Channel
Figure 12. Retail Channel
Figure 13. E-Commerce Channel
Figure 14. Global Transdermal Therapeutic Systems (TTS) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Transdermal Therapeutic Systems (TTS) Market Size 2016-2027 (US$ Million)
Figure 16. Global Transdermal Therapeutic Systems (TTS) Sales 2016-2027 (M Units)
Figure 17. Global Transdermal Therapeutic Systems (TTS) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 18. Transdermal Therapeutic Systems (TTS) Sales Share by Manufacturers in 2020
Figure 19. Global Transdermal Therapeutic Systems (TTS) Revenue Share by Manufacturers in 2020
Figure 20. The Global 5 and 10 Largest Transdermal Therapeutic Systems (TTS) Players: Market Share by Revenue in 2020
Figure 21. Transdermal Therapeutic Systems (TTS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 22. Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Region (2016-2021)
Figure 23. Global Transdermal Therapeutic Systems (TTS) Sales Market Share by Region in 2020
Figure 24. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Region (2016-2021)
Figure 25. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Region in 2020
Figure 26. U.S. Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Canada Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Germany Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. France Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. U.K. Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Italy Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Russia Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. China Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Japan Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. South Korea Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. India Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Australia Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Taiwan Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Indonesia Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Thailand Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Malaysia Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Philippines Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Vietnam Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Mexico Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Brazil Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Argentina Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Turkey Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Saudi Arabia Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. UAE Transdermal Therapeutic Systems (TTS) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. Sales Market Share of Transdermal Therapeutic Systems (TTS) by Type (2016-2021)
Figure 51. Sales Market Share of Transdermal Therapeutic Systems (TTS) by Application (2016-2021)
Figure 52. Sales Market Share of Transdermal Therapeutic Systems (TTS) by Application in 2020
Figure 53. Revenue Share of Transdermal Therapeutic Systems (TTS) by Application (2016-2021)
Figure 54. Revenue Share of Transdermal Therapeutic Systems (TTS) by Application in 2020
Figure 55. Manufacturing Cost Structure of Transdermal Therapeutic Systems (TTS)
Figure 56. Manufacturing Process Analysis of Transdermal Therapeutic Systems (TTS)
Figure 57. Transdermal Therapeutic Systems (TTS) Industrial Chain Analysis
Figure 58. Channels of Distribution
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed